May 27, 2018 8:04 PM ET

Biotechnology

Company Overview of Exosome Diagnostics, Inc.

Company Overview

Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company develops exosome-based diagnostics technology platform that harvests comprehensive and dynamic molecular information contained within exosomes from various fresh or frozen biofluids to deliver personalized healthcare to guide treatment decisions and in real-time along the entire patient care continuum. It also develops MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously interrogates exosomal RNA (exoRNA) and circulating tumor DNA (ctDNA) in a single assay, as well as identifies clinically actionable and functionally ...

266 Second Avenue

Suite 200

Waltham, MA 02451

United States

Founded in 2008

Phone:

617-588-0500

Fax:

617-588-0580

Key Executives for Exosome Diagnostics, Inc.

Chief Executive Officer and President
Chief Financial Officer
Age: 46
Chief Science Officer and Founding Scientist
Head of Informatics
Head of Commercial Diagnostics
Compensation as of Fiscal Year 2017.

Exosome Diagnostics, Inc. Key Developments

Exosome Diagnostics, Inc. Continues to Expand Coverage Reach for its EPI Test

Exosome Diagnostics, Inc. has continued to make significant progress in expanding contracts to provide laboratory services and ExoDx® Prostate(IntelliScore) (EPI) testing through both public and private payers in the United States. Contracts executed in March and April 2018 have increased total covered lives from 82 million to 110 million plan members across the United States. This increase is based on a series of coverage decisions from regional private payers where are marketing the EPI test. This includes association member plans, independent community plans and state Medicaid programs. The company is advancing contracting decisions with a number of additional payers across the United States and expects to announce additional coverage determinations over the remainder of 2018.

Exosome Diagnostics Appoints Grannum Sant as Head of Medical Affairs

Exosome Diagnostics, Inc. announced the appointment of Dr. Grannum Sant as Head of Medical Affairs. In his more than two decades with Tufts University, Dr. Sant served as Professor and Chair of Urology at Tufts University School of Medicine, where he still holds an appointment as Professor of Urology. In addition to his impressive experience within clinical urology, Dr. Sant made an international name for himself as a pharma medical affairs and clinical development executive; serving as VP Medical Affairs for Oncology/Urology at Sanofi-Aventis US, VP and Head of Medical Affairs for Rare Diseases at Genzyme. Most recently, Dr. Sant was Medical Affairs Lead for OPKO Health Inc.

Exosome Diagnostics, Inc. Partners with Intezyne, Inc. to Develop Exosomal RNA-Based Assay for Novel Cancer Resistance Pathway Inhibitor

Exosome Diagnostics, Inc. announced a collaboration agreement with Intezyne, Inc. to design and validate a highly sensitive exosomal RNA based assay for use in Intezyne’s Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and other cancers in combination with existing anti-cancer therapies. The assay leverages Exosome Diagnostics’ ExoLution isolation kit, a cGMP-grade exosome RNA isolation platform, and is intended for the stratification and long-term monitoring of patients. Leveraging the company’s capabilities across both nucleic acid interrogation (cell free DNA + Exosomal RNA) and exosomal protein analysis, Exosome has already built a substantial portfolio of liquid biopsy and companion diagnostics.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 21, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Exosome Diagnostics, Inc., please visit www.exosomedx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.